{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:11:40Z","timestamp":1786990300500,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ijantimicag.2009.11.013","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T05:54:43Z","timestamp":1262757283000},"page":"278-281","source":"Crossref","is-referenced-by-count":77,"title":["Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei"],"prefix":"10.1016","volume":"35","author":[{"given":"Zhi-Dong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L.","family":"DuPont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2009.11.013_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/338834","article-title":"Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay)","volume":"185","author":"Jiang","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib2","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1086\/323814","article-title":"Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial","volume":"33","author":"DuPont","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1128\/AAC.45.1.212-216.2001","article-title":"In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions","volume":"45","author":"Gomi","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1469-0691.2004.00997.x","article-title":"Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci","volume":"10","author":"DuPont","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 8","key":"10.1016\/j.ijantimicag.2009.11.013_bib5","doi-asserted-by":"crossref","first-page":"S571","DOI":"10.1086\/432954","article-title":"Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin","volume":"41","author":"DuPont","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib6","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1128\/AAC.3.4.456","article-title":"Relationships between curing of the F episome by rifampin and by acridine orange in Escherichia coli","volume":"3","author":"Riva","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib8","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI, 2006."},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0003-2697(80)90338-3","article-title":"Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates","volume":"102","author":"Heussen","year":"1980","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/CDLI.11.3.548-551.2004","article-title":"Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli","volume":"11","author":"Huang","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/mpat.2001.0470","article-title":"Matrix metalloproteinases induction by pseudomonal virulence factors and inflammatory cytokines in vitro","volume":"31","author":"Miyajima","year":"2001","journal-title":"Microb Pathog"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib12","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1128\/IAI.69.9.5661-5670.2001","article-title":"Production of matrix metalloproteinases in response to mycobacterial infection","volume":"69","author":"Quiding-Jarbrink","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/07853890600800103","article-title":"Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation","volume":"38","author":"Sorsa","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib14","first-page":"483","article-title":"In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.","volume":"13","author":"Ripa","year":"1987","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.ijantimicag.2009.11.013_bib15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4269\/ajtmh.2006.74.1060","article-title":"A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers\u2019 diarrhea","volume":"74","author":"Taylor","year":"2006","journal-title":"Am J Trop Med Hyg"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909005470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909005470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T08:37:09Z","timestamp":1590482229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857909005470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0924857909005470"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.11.013","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}